Ziconotide Production Cost Reports

The report provides a detailed analysis essential for establishing a Ziconotide production plant. It encompasses all critical aspects necessary for Ziconotide production, including the cost of Ziconotide production, Ziconotide plant cost, Ziconotide production costs, and the overall Ziconotide production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Ziconotide production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Ziconotide is a synthetic peptide that works as a selective N-type calcium channel blocker. It is approved by the FDA for intrathecal infusion to manage severe chronic pain in adults who do not respond to other treatments like systemic analgesics or intrathecal morphine. It targets intractable pain from both cancer (malignant) and non-cancer (non-malignant) causes, like neuropathic pain, failed back surgery syndrome, or complex regional pain syndrome.

It is delivered directly into the spinal fluid via an implanted pump to block pain signal transmission in the spinal cord without opioid-like effects or addiction risk. It is also utilised in acute postoperative pain, spinal cord injury-related neuropathic pain, and as an adjunct in multimodal intrathecal therapy with drugs like bupivacaine or clonidine. Its common side effects include dizziness, nausea, ataxia and unsteady gait, somnolence and drowsiness, confusion, headache, etc.

The market for Ziconotide is driven by increasing demand for non-opioid alternatives to manage severe chronic pain. The rising cases of refractory cancer and non-cancer pain conditions, and advancements in intrathecal drug delivery systems like implantable pumps expands its applications. Its usage as a unique N-type calcium channel blocker for patients that are intolerant to opioids fuels its market. The industrial Ziconotide procurement is driven by high production costs as a complex synthetic peptide that needs specialised solid-phase synthesis and GMP-compliant purification. Also, limited API suppliers with DMFs and CEPs creating supply dependencies, mandatory intrathecal pump infrastructure adding device-related expenses, along with strict reimbursement policies impacts its sourcing strategies.

Raw Material for Ziconotide Production

According to the Ziconotide production plant project report, the key raw materials used in the production of Ziconotide include Fmoc-protected amino acids, HBTU, NMM, DIC, HOBt, and cystine.

Production Process of Ziconotide

The extensive Ziconotide production cost report consists of the following major industrial production process:

1. From Fmoc-Protected Amino Acids: The production process of Ziconotide involves an efficient solid-phase peptide synthesis (SPPS) of a 25-mer linear precursor peptide. This takes places using Fmoc chemistry on resin in DMF, where couplings for residues 1-15 employ HBTU/NMM and residues 16-25 use DIC/HOBt to achieve high crude purity. The fully protected peptide is then cleaved from the resin, globally deprotected under standard acidolytic conditions, precipitated, and purified to yield the linear precursor with 99% purity. The purified peptide is then subjected to native oxidative folding in aqueous buffer using a modified cysteine–cystine redox system at low peptide concentration, to give Ziconotide.

Ziconotide is a synthetic 25-amino acid peptide neurotoxin with a molecular formula of C102H172N36O32S7 and a molecular weight of 2639.19-2639.2 Da. It has an XLogP3 value of -14, indicating high hydrophilicity. It has 42 hydrogen bond donors, 46 acceptors, 40 rotatable bonds, topological polar surface area of 1310 Ų. It is freely water-soluble (hydrophilic), practically insoluble in methyl t-butyl ether, formulated as a sterile preservative-free isotonic solution. It shows 50% human plasma protein bound, low membrane permeability due to size, CSF clearance 0.38 mL/min, and plasma clearance 270 mL/min. All these physical and chemical properties make it useful as a selective N-type calcium channel blocker.